Lyman break and ultraviolet-selected galaxies at z ̃ 1-I. Stellar populations from the ALHAMBRA survey

We take advantage of the exceptional photometric coverage provided by the combination of GALEX data in the ultraviolet (UV) and the ALHAMBRA survey in the optical and near-infrared to analyse the physical properties of a sample of 1225 GALEX-selected Lyman break galaxies (LBGs) at 0.8 ≲ z ≲ 1.2 that are located in the COSMOS field. This is the largest sample of LBGs studied in this redshift range to date. According to a spectral energy distribution (SED) fitting with synthetic stellar population templates, we find that LBGs at z ̃ 1 are mostly young galaxies with a median age of 341 Myr and have intermediate dust attenuation, (Es(B - V)) ̃ 0.20. Owing to the selection criterion, LBGs at z ̃ 1 are UV-bright galaxies and have a high dust-corrected total star formation rate (SFR), with a median value of 16.9M⊙ yr-1. Their median stellar mass is log (M*/M⊙) = 9.74. We find that the dustcorrected total SFR of LBGs increases with stellar mass and that the specific SFR is lower for more massive galaxies (downsizing scenario). Only 2 per cent of the galaxies selected through the Lyman break criterion have an active galactic nucleus nature. LBGs at z ̃ 1 are located mostly over the blue cloud of the colour-magnitude diagram of galaxies at their redshift, with only the oldest and/or the dustiest deviating towards the green valley and red sequence. Morphologically, 69 per cent of LBGs are disc-like galaxies, with the fractions of interacting, compact, or irregular systems being much lower, below 12 per cent. LBGs have a median effective radius of 2.5 kpc, and larger galaxies have a higher total SFR and stellar mass. Compared with their high-redshift analogues, we find evidence that LBGs at lower redshifts are larger, redder in the UV continuum, and have a major presence of older stellar populations in their SEDs. However, we do not find significant differences in the distributions of stellar mass or dust attenuation.NASA NAS5-26555NASA Office of Space Science NNX09AF08GEuropean Southern Observatory LP175.A-0839.Junta de Andalucia TIC-114, P08-TIC03531Ministerio de Economía y Competitividad AYA2011-29517-C03- 01, AYA2010-1516

Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency

Background Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most common inherited defect in the mitochondrial fatty acid oxidation pathway, resulting in significant morbidity and mortality in undiagnosed patients. Newborn screening (NBS) has considerably improved MCADD outcome, but the risk of complication remains in some patients. The aim of this study was to evaluate the relationship between genotype, biochemical parameters and clinical data at diagnosis and during follow-up, in order to optimize monitoring of these patients. Methods We carried out a multicenter study in southwest Europe, of MCADD patients detected by NBS. Evaluated NBS data included free carnitine (C0) and the acylcarnitines C8, C10, C10:1 together with C8/C2 and C8/C10 ratios, clinical presentation parameters and genotype, in 45 patients. Follow-up data included C0 levels, duration of carnitine supplementation and occurrence of metabolic crises. Results C8/C2 ratio and C8 were the most accurate biomarkers of MCADD in NBS. We found a high number of patients homozygous for the prevalent c.985A > G mutation (75%). Moreover, in these patients C8, C8/C10 and C8/C2 were higher than in patients with other genotypes, while median value of C0 was significantly lower (23 μmol/L vs 36 μmol/L). The average follow-up period was 43 months. To keep carnitine levels within the normal range, carnitine supplementation was required in 82% of patients, and for a longer period in patients homozygotes for the c.985A>G mutation than in patients with other genotypes (average 31 vs 18 months). Even with treatment, median C0 levels remained lower in homozygous patients than in those with other genotypes (14 μmol/L vs 22 μmol/L). Two patients died and another three suffered a metabolic crisis, all of whom were homozygous for the c.985 A>G mutation. Conclusions Our data show a direct association between homozygosity for c.985A>G and lower carnitine values at diagnosis, and a higher dose of carnitine supplementation for maintenance within the normal range. This study contributes to a better understanding of the relationship between genotype and phenotype in newborn patients with MCADD detected through screening which could be useful in improving follow-up strategies and clinical outcome

The OTELO survey. A case study of [O III]4959,5007 emitters at <z> = 0.83

The OTELO survey is a very deep, blind exploration of a selected region of the Extended Groth Strip and is designed for finding emission-line sources (ELSs). The survey design, observations, data reduction, astrometry, and photometry, as well as the correlation with ancillary data used to obtain a final catalogue, including photo-z estimates and a preliminary selection of ELS, were described in a previous contribution. Here, we aim to determine the main properties and luminosity function (LF) of the [O III] ELS sample of OTELO as a scientific demonstration of its capabilities, advantages, and complementarity with respect to other surveys. The selection and analysis procedures of ELS candidates obtained using tunable filter (TF) pseudo-spectra are described. We performed simulations in the parameter space of the survey to obtain emission-line detection probabilities. Relevant characteristics of [O III] emitters and the LF([O III]), including the main selection biases and uncertainties, are presented. A total of 184 sources were confirmed as [O III] emitters at a mean redshift z=0.83. The minimum detectable line flux and equivalent width (EW) in this ELS sample are $\sim$5 $\times$ 10$^{-19}$ erg s$^{-1}$ cm$^{2}$ and $\sim$6 \AA, respectively. We are able to constrain the faint-end slope ($\alpha = -1.03\pm0.08$) of the observed LF([O III]) at z=0.83. This LF reaches values that are approximately ten times lower than those from other surveys. The vast majority (84\%) of the morphologically classified [O III] ELSs are disc-like sources, and 87\% of this sample is comprised of galaxies with stellar masses of M$_\star$ $<$ 10$^{10}$ M$_{\odot}$.Comment: v1: 16 pages, 6 figures. Accepted in Astronomy \& Astrophysics. v2: Author added in metadat

Galaxy classification: deep learning on the OTELO and COSMOS databases

Context. The accurate classification of hundreds of thousands of galaxies observed in modern deep surveys is imperative if we want to understand the universe and its evolution. Aims. Here, we report the use of machine learning techniques to classify early- and late-type galaxies in the OTELO and COSMOS databases using optical and infrared photometry and available shape parameters: either the Sersic index or the concentration index. Methods. We used three classification methods for the OTELO database: 1) u-r color separation , 2) linear discriminant analysis using u-r and a shape parameter classification, and 3) a deep neural network using the r magnitude, several colors, and a shape parameter. We analyzed the performance of each method by sample bootstrapping and tested the performance of our neural network architecture using COSMOS data. Results. The accuracy achieved by the deep neural network is greater than that of the other classification methods, and it can also operate with missing data. Our neural network architecture is able to classify both OTELO and COSMOS datasets regardless of small differences in the photometric bands used in each catalog. Conclusions. In this study we show that the use of deep neural networks is a robust method to mine the cataloged dataComment: 20 pages, 10 tables, 14 figures, Astronomy and Astrophysics (in press

Physical properties of Lyman-alpha emitters at z∼0.3z\sim 0.3 from UV-to-FIR measurements

The analysis of the physical properties of low-redshift Ly$\alpha$ emitters (LAEs) can provide clues in the study of their high-redshift analogues. At $z \sim 0.3$, LAEs are bright enough to be detected over almost the entire electromagnetic spectrum and it is possible to carry out a more precise and complete study than at higher redshifts. In this study, we examine the UV and IR emission, dust attenuation, SFR and morphology of a sample of 23 GALEX-discovered star-forming (SF) LAEs at $z \sim 0.3$ with direct UV (GALEX), optical (ACS) and FIR (PACS and MIPS) data. Using the same UV and IR limiting luminosities, we find that LAEs at $z\sim 0.3$ tend to be less dusty, have slightly higher total SFRs, have bluer UV continuum slopes, and are much smaller than other galaxies that do not exhibit Ly$\alpha$ emission in their spectrum (non-LAEs). These results suggest that at $z \sim 0.3$ Ly$\alpha$ photons tend to escape from small galaxies with low dust attenuation. Regarding their morphology, LAEs belong to Irr/merger classes, unlike non-LAEs. Size and morphology represent the most noticeable difference between LAEs and non-LAEs at $z \sim 0.3$. Furthermore, the comparison of our results with those obtained at higher redshifts indicates that either the Ly$\alpha$ technique picks up different kind of galaxies at different redshifts or that the physical properties of LAEs are evolving with redshift.Comment: Accepted for publication in Ap

Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience

Background: Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase. Its clinical presentation is very heterogeneous and poorly understood in adults. The aim of this study was to describe the clinical manifestations of MPS IVA in adult patients in Spain and to assess their health-related quality of life (HRQoL). Results: Thirty-three patients from nine reference centres participated in the study. The median age was 32 (interquartile range [IQR]: 20.5–40.5) years. The phenotype was classical in 54.5% of patients, intermediate in 33.3% of patients, and non-classical in 12.1% of patients. The most common clinical manifestation was bone dysplasia, with a median height of 118 (IQR: 106–136) cm. Other frequent clinical manifestations were hearing loss (75.7%), ligamentous laxity (72.7%), odontoid dysplasia (69.7%), limb deformities that required orthopaedic aids (mainly hip dysplasia and genu valgus) (63.6%), and corneal clouding (60.6%). In addition, 36.0% of patients had obstructive sleep apnoea/hypopnoea syndrome and 33.3% needed non-invasive ventilation. Cervical surgery and varisation osteotomy were the most common surgical interventions (36.4% each). Almost 80% of patients had mobility problems and 36.4% used a wheelchair at all times. Furthermore, 87.9% needed help with self-care, 33.3% were fully dependent, and 78.8% had some degree of pain. HRQoL according to the health assessment questionnaire was 1.43 (IQR: 1.03–2.00) in patients with the non-classical phenotype, but 2.5 (IQR: 1.68–3.00) in those with the classical phenotype. Seven patients were initiated on enzyme replacement therapy (ERT), but two of them were lost to follow-up. Lung function improved in four patients and slightly worsened in one patient. The distance achieved in the six-minute walk test increased in the four patients who could perform it. HRQoL was better in patients treated with elosulfase alfa, with a median (IQR) of 1.75 (1.25–2.34) versus 2.25 (1.62–3.00) in patients not treated with ERT. Conclusions: The study provides real-world data on patients with MPS IVA. Limited mobility, difficulties with self-care, dependence, and pain were common, together with poor HRQoL. The severity and heterogeneity of clinical manifestations require the combined efforts of multidisciplinary teams

PACS-Herschel FIR detections of Lyman-alpha emitters at 2.0<z<3.5

In this work we analyze the physical properties of a sample of 56 spectroscopically selected star-forming (SF) Ly$\alpha$ emitting galaxies at 2.0$\lesssim$z$\lesssim$3.5 using both a spectral energy distribution (SED) fitting procedure from rest-frame UV to mid-IR and direct 160$\mu$m observations taken with the Photodetector Array Camera & Spectrometer (PACS) instrument onboard \emph{Herschel Space Observatory}. We define LAEs as those Ly$\alpha$ emitting galaxies whose rest-frame Ly$\alpha$ equivalent widths (Ly$\alpha$ EW$_{rest-frame}$) are above 20\AA, the typical threshold in narrow-band searches. Ly$\alpha$ emitting galaxies with Ly$\alpha$ EW$_{rest-frame}$ are called non-LAEs. As a result of an individual SED fitting for each object, we find that the studied sample of LAEs contains galaxies with ages mostly below 100Myr and a wide variety of dust attenuations, SFRs, and stellar masses. The heterogeneity in the physical properties is also seen in the morphology, ranging from bulge-like galaxies to highly clumpy systems. In this way, we find that LAEs at 2.0$\lesssim$z$\lesssim$3.5 are very diverse, and do not have a bimodal nature, as suggested in previous works. Furthermore, the main difference between LAEs and non-LAEs is their dust attenuation, because LAEs are not as dusty as non-LAEs. On the FIR side, four galaxies of the sample (two LAEs and two non-LAEs) have PACS-FIR counterparts. Their total IR luminosity place all of them in the ULIRG regime and are all dusty objects, with A$_{1200}$$\gtrsim$4mag. This is an indication from direct FIR measurements that dust and Ly$\alpha$ emission are not mutually exclusive. This population of red and dusty LAEs is not seen at z$\sim$0.3, suggesting an evolution with redshift of the IR nature of galaxies selected via their Ly$\alpha$ emission.Comment: Accepted for publication in A&

Lyman break and UV-selected galaxies at z ~ 1: II. PACS-100um/160um FIR detections

We report the PACS-100um/160um detections of a sample of 42 GALEX-selected and FIR-detected Lyman break galaxies (LBGs) at z ~ 1 located in the COSMOS field and analyze their ultra-violet (UV) to far-infrared (FIR) properties. The detection of these LBGs in the FIR indicates that they have a dust content high enough so that its emission can be directly detected. According to a spectral energy distribution (SED) fitting with stellar population templates to their UV-to-near-IR observed photometry, PACS-detected LBGs tend to be bigger, more massive, dustier, redder in the UV continuum, and UV-brighter than PACS-undetected LBGs. PACS-detected LBGs at z ~ 1 are mostly disk-like galaxies and are located over the green-valley and red sequence of the color-magnitude diagram of galaxies at their redshift. By using their UV and IR emission, we find that PACS-detected LBGs tend to be less dusty and have slightly higher total star-formation rates (SFRs) than other PACS-detected UV-selected galaxies within their same redshift range. As a consequence of the selection effect due to the depth of the FIR observations employed, all our PACS-detected LBGs are LIRGs. However, none of them are in the ULIRG regime, where the FIR observations are complete. The finding of ULIRGs-LBGs at higher redshifts suggests an evolution of the FIR emission of LBGs with cosmic time. In an IRX-$\beta$ diagram, PACS-detected LBGs at z ~ 1 tend to be located around the relation for local starburst similarly to other UV-selected PACS-detected galaxies at their same redshift. Consequently, the dust-correction factors obtained with their UV continuum slope allow to determine their total SFR, unlike at higher redshifts. However, the dust attenuation derived from UV to NIR SED fitting overestimates the total SFR for most of our PACS-detected LBGs in age-dependent way: the overestimation factor is higher in younger galaxies.Comment: Accepted for publication in MNRA

The OTELO survey I. Description, data reduction, and multi-wavelength catalogue

ABSTRACT: Context. The evolution of galaxies through cosmic time is studied observationally by means of extragalactic surveys. The usefulness of these surveys is greatly improved by increasing the cosmological volume, in either depth or area, and by observing the same targets in different wavelength ranges. A multi-wavelength approach using different observational techniques can compensate for observational biases. Aims. The OTELO survey aims to provide the deepest narrow-band survey to date in terms of minimum detectable flux and emission line equivalent width in order to detect the faintest extragalactic emission line systems. In this way, OTELO data will c omplements other broad-band, narrow-band, and spectroscopic surveys. Methods. The red tunable filter of the OSIRIS instrument on the 10.4 m Gran Telescopio Canarias (GTC) is used to scan a spectral window centred at 9175 Å, which is free from strong sky emission lines, with a sampling interval of 6 Å and a bandwidth of 12 Å in the most deeply explored EGS region. Careful data reduction using improved techniques for sky ring subtraction, accurate astrometry, photometric calibration, and source extraction enables us to compile the OTELO catalogue. This catalogue is complemented with ancillary data ranging from deep X-ray to far-infrared, including high resolution HST images, which allow us to segregate the different types of targets, derive precise photometric redshifts, and obtain the morphological classification of the extragalactic objects detected. Results. The OTELO multi-wavelength catalogue contains 11 237 entries and is 50% complete at AB magnitude 26.38. Of these sources, 6600 have photometric redshifts with an uncertainty δ z phot better than 0.2 (1+z phot). A total of 4336 of these sources correspond to preliminary emission line candidates, which are complemented by 81 candidate stars and 483 sources that qualify as absorption line systems. The OTELO survey results will be released to the public on the second half of 2019.This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO) under the grants AYA2013-46724-P, AYA2014-58861-C3-1-P, AYA2014-58861-C3-2-P, AYA2014-58861-C3-3-P, AYA2016-75808-R, AYA2016-75931-C2-2-P, AYA2017-88007-C3-1-P and AYA2017-88007-C3-2-P

Efficacy and safety of preoperative preparation with Lugol''s iodine solution in euthyroid patients with Graves’ disease (LIGRADIS Trial): Study protocol for a multicenter randomized trial

Background: Currently, both the American Thyroid Association and the European Thyroid Association recommend preoperative preparation with Lugol''s Solution (LS) for patients undergoing thyroidectomy for Graves’ Disease (GD), but their recommendations are based on low-quality evidence. The LIGRADIS trial aims to provide evidence either to support or refute the systematic use of LS in euthyroid patients undergoing thyroidectomy for GD. Methods: A multicenter randomized controlled trial will be performed. Patients =18 years of age, diagnosed with GD, treated with antithyroid drugs, euthyroid and proposed for total thyroidectomy will be eligible for inclusion. Exclusion criteria will be prior thyroid or parathyroid surgery, hyperparathyroidism that requires associated parathyroidectomy, thyroid cancer that requires adding a lymph node dissection, iodine allergy, consumption of lithium or amiodarone, medically unfit patients (ASA-IV), breastfeeding women, preoperative vocal cord palsy and planned endoscopic, video-assisted or remote access surgery. Between January 2020 and January 2022, 270 patients will be randomized for either receiving or not preoperative preparation with LS. Researchers will be blinded to treatment assignment. The primary outcome will be the rate of postoperative complications: hypoparathyroidism, recurrent laryngeal nerve injury, hematoma, surgical site infection or death. Secondary outcomes will be intraoperative events (Thyroidectomy Difficulty Scale score, blood loss, recurrent laryngeal nerve neuromonitoring signal loss), operative time, postoperative length of stay, hospital readmissions, permanent complications and adverse events associated to LS. Conclusions: There is no conclusive evidence supporting the benefits of preoperative treatment with LS in this setting. This trial aims to provide new insights into future Clinical Practice Guidelines recommendations. Trial registration: ClinicalTrials.gov identifier: NCT03980132. © 202